Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Keros Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 20.6% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $28.7 million, down 17.71%, while the annual FY2025 figure was $28.7 million, 17.71% down from the prior year.
  • Share-based Compensation reached $7.3 million in Q4 2025 per KROS's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.2 million in Q4 2024 to a low of $2.5 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $6.1 million, with a median of $6.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 20683.33% in 2021, then crashed 54.79% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.3 million in 2021, then skyrocketed by 44.04% to $4.7 million in 2022, then skyrocketed by 54.32% to $7.3 million in 2023, then rose by 25.61% to $9.2 million in 2024, then fell by 20.6% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Share-based Compensation are $7.3 million (Q4 2025), $4.0 million (Q3 2025), and $8.5 million (Q2 2025).